CVE-2023-33365

CVE-2023-33365 is a high-severity vulnerability in Supremainc Biostar 2 with a CVSS 3.x base score of 7.5. It is not currently listed as actively exploited by CISA, and its EPSS exploit-prediction score is low. The underlying weakness is classified as CWE-22.

Key facts

Description

A path traversal vulnerability exists in Suprema BioStar 2 before 2.9.1, which allows unauthenticated attackers to fetch arbitrary files from the server's web server.

Frequently asked questions

What is CVE-2023-33365?
A path traversal vulnerability exists in Suprema BioStar 2 before 2.9.1, which allows unauthenticated attackers to fetch arbitrary files from the server's web server.
How severe is CVE-2023-33365?
CVE-2023-33365 has a CVSS 3.x base score of 7.5, rated high severity. It is exploitable over network with low attack complexity, requires no privileges and no user interaction. Impact on confidentiality is high, integrity none, and availability none.
Is CVE-2023-33365 being actively exploited?
It is not currently listed in CISA's KEV catalog. Its EPSS exploit-prediction score is 1% (51st percentile), an estimate of the probability of exploitation in the next 30 days.
What products are affected by CVE-2023-33365?
CVE-2023-33365 affects Supremainc Biostar 2. See the affected-products list for the exact vulnerable versions.
How do I fix CVE-2023-33365?
Review the linked vendor and NVD advisories for patched versions and mitigations, then upgrade or apply the recommended workaround. Given its high severity, prioritise patching exposed systems.
When was CVE-2023-33365 published?
CVE-2023-33365 was published on 2023-08-03 and last updated on 2026-06-17.

References

Affected products (1)

More vulnerabilities in Supremainc Biostar 2

All CVEs affecting Supremainc Biostar 2 →

Other CWE-22 (Path Traversal) vulnerabilities

Browse all CWE-22 (Path Traversal) vulnerabilities →